Prelude Therapeutics
PRLD on XNAS, Prelude Therapeutics Incorporated
Measures activity, not value. Not investment advice.
Shares sold short (30 Oct 2026)
4.2M
-18% vs the report before
Short interest, % of shares outstanding
5.2%
80.1M shares outstanding (11 Nov 2026)
Days to cover
9.1
short interest / daily volume
Short sale volume share (20 Nov 2026)
60%
1-year median 47%
Sharp changes
13
short interest spike
FINRA short interest by settlement date (the 15th and the last business day of each month). FINRA publishes each report 7 business days after its settlement date. Dashed: 3-year median.
See the numbers
| 30 Oct 2026: 4.2M shares sold short, 9.1 days to cover |
| 15 Oct 2026: 5.1M shares sold short, 11.5 days to cover |
| 30 Sep 2026: 4.6M shares sold short, 7.9 days to cover |
| 15 Sep 2026: 3.6M shares sold short, 9.0 days to cover |
| 31 Aug 2026: 3.6M shares sold short, 5.6 days to cover |
| 14 Aug 2026: 3.8M shares sold short, 9.8 days to cover |
| 31 Jul 2026: 3.7M shares sold short, 9.3 days to cover |
| 15 Jul 2026: 3.3M shares sold short, 9.5 days to cover |
| 30 Jun 2026: 2.8M shares sold short, 3.5 days to cover |
| 15 Jun 2026: 1.8M shares sold short, 6.3 days to cover |
| 29 May 2026: 1.7M shares sold short, 5.4 days to cover |
| 15 May 2026: 1.9M shares sold short, 3.5 days to cover |
| 30 Apr 2026: 1.6M shares sold short, 2.7 days to cover |
| 15 Apr 2026: 1.8M shares sold short, 5.2 days to cover |
| 31 Mar 2026: 2.3M shares sold short, 13.8 days to cover |
| 13 Mar 2026: 2.3M shares sold short, 8.1 days to cover |
| 27 Feb 2026: 2.3M shares sold short, 6.2 days to cover |
| 13 Feb 2026: 2.4M shares sold short, 8.9 days to cover |
| 30 Jan 2026: 2.1M shares sold short, 4.8 days to cover |
| 15 Jan 2026: 1.7M shares sold short, 3.1 days to cover |
| 31 Dec 2025: 1.5M shares sold short, 2.6 days to cover |
| 15 Dec 2025: 1.3M shares sold short, 3.3 days to cover |
| 28 Nov 2025: 996K shares sold short, 2.0 days to cover |
| 14 Nov 2025: 1.3M shares sold short, 1.0 days to cover |
| 31 Oct 2025: 567K shares sold short, 2.1 days to cover |
| 15 Oct 2025: 515K shares sold short, 2.4 days to cover |
| 30 Sep 2025: 601K shares sold short, 1.6 days to cover |
| 15 Sep 2025: 538K shares sold short, 4.1 days to cover |
| 29 Aug 2025: 531K shares sold short, 1.8 days to cover |
| 15 Aug 2025: 510K shares sold short, 4.5 days to cover |
| 31 Jul 2025: 595K shares sold short, 4.3 days to cover |
| 15 Jul 2025: 521K shares sold short, 5.0 days to cover |
| 30 Jun 2025: 546K shares sold short, 1.9 days to cover |
| 13 Jun 2025: 841K shares sold short, 4.8 days to cover |
| 30 May 2025: 946K shares sold short, 5.9 days to cover |
| 15 May 2025: 878K shares sold short, 7.9 days to cover |
| 30 Apr 2025: 979K shares sold short, 8.3 days to cover |
| 15 Apr 2025: 2.3M shares sold short, 11.8 days to cover |
| 31 Mar 2025: 2.4M shares sold short, 7.5 days to cover |
| 14 Mar 2025: 2.3M shares sold short, 13.2 days to cover |
| 28 Feb 2025: 2.2M shares sold short, 12.8 days to cover |
| 14 Feb 2025: 3.1M shares sold short, 14.1 days to cover |
| 31 Jan 2025: 3.1M shares sold short, 12.4 days to cover |
| 15 Jan 2025: 3.1M shares sold short, 11.4 days to cover |
| 31 Dec 2024: 3.4M shares sold short, 3.3 days to cover |
| 13 Dec 2024: 3.3M shares sold short, 7.1 days to cover |
| 29 Nov 2024: 3.1M shares sold short, 9.9 days to cover |
| 15 Nov 2024: 2.9M shares sold short, 7.9 days to cover |
| 31 Oct 2024: 2.9M shares sold short, 7.0 days to cover |
| 15 Oct 2024: 2.5M shares sold short, 14.9 days to cover |
| 30 Sep 2024: 2.5M shares sold short, 5.7 days to cover |
| 13 Sep 2024: 3.3M shares sold short, 6.3 days to cover |
| 30 Aug 2024: 2.4M shares sold short, 10.9 days to cover |
| 15 Aug 2024: 1.4M shares sold short, 9.3 days to cover |
| 31 Jul 2024: 771K shares sold short, 4.0 days to cover |
| 15 Jul 2024: 528K shares sold short, 4.3 days to cover |
| 28 Jun 2024: 560K shares sold short, 8.8 days to cover |
| 14 Jun 2024: 567K shares sold short, 14.6 days to cover |
| 31 May 2024: 585K shares sold short, 12.4 days to cover |
| 15 May 2024: 609K shares sold short, 18.3 days to cover |
What the numbers say
- 4.2M shares sold short on 30 Oct 2026, 5.2% of shares outstanding, 9.1 days to cover; -18% on the report before (published by FINRA on 10 Nov 2026).
Every measure from this source
Short interest is a position, reported twice a month. Short sale volume is a different measure: the share of each day's trading on off-exchange venues that was a short sale. Market makers sell short routinely, so 40% to 50% is normal.
Sharp changes
13 in all loaded history, strongest first
Prelude Therapeutics had 3.4M shares sold short in the 31 Dec 2024 report, 7.6× the same report last year.
Same report last year: 447K; its normal report is 626K.
See the evidence
- This period
- 3.4M (the 31 Dec 2024 report)
- Normal report (median of 24 earlier)
- 626K
- Typical spread (median absolute deviation)
- 134K
- How far from its usual level
- +13.9
- Same report last year
- 447K
- History used
- 1,553 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.
Prelude Therapeutics had 3.3M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.
Same report last year: 1.7M; its normal report is 626K.
See the evidence
- This period
- 3.3M (the 13 Sep 2024 report)
- Normal report (median of 24 earlier)
- 626K
- Typical spread (median absolute deviation)
- 109K
- How far from its usual level
- +16.7
- Same report last year
- 1.7M
- History used
- 1,444 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.
Prelude Therapeutics had 3.3M shares sold short in the 13 Dec 2024 report, 4.8× the same report last year.
Same report last year: 680K; its normal report is 626K.
See the evidence
- This period
- 3.3M (the 13 Dec 2024 report)
- Normal report (median of 24 earlier)
- 626K
- Typical spread (median absolute deviation)
- 113K
- How far from its usual level
- +15.7
- Same report last year
- 680K
- History used
- 1,535 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.
Prelude Therapeutics had 3.1M shares sold short in the 31 Jan 2025 report, 6.0× the same report last year.
Same report last year: 522K; its normal report is 707K.
See the evidence
- This period
- 3.1M (the 31 Jan 2025 report)
- Normal report (median of 24 earlier)
- 707K
- Typical spread (median absolute deviation)
- 194K
- How far from its usual level
- +8.5
- Same report last year
- 522K
- History used
- 1,584 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.
Prelude Therapeutics had 3.1M shares sold short in the 15 Jan 2025 report, 6.9× the same report last year.
Same report last year: 451K; its normal report is 637K.
See the evidence
- This period
- 3.1M (the 15 Jan 2025 report)
- Normal report (median of 24 earlier)
- 637K
- Typical spread (median absolute deviation)
- 134K
- How far from its usual level
- +12.5
- Same report last year
- 451K
- History used
- 1,568 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.
Prelude Therapeutics had 3.1M shares sold short in the 29 Nov 2024 report, 4.1× the same report last year.
Same report last year: 741K; its normal report is 626K.
See the evidence
- This period
- 3.1M (the 29 Nov 2024 report)
- Normal report (median of 24 earlier)
- 626K
- Typical spread (median absolute deviation)
- 109K
- How far from its usual level
- +15.0
- Same report last year
- 741K
- History used
- 1,521 days
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Check it at the source: FINRA short interest data.